S&P Futures
5,901.75 +5.25 (+0.09%) Dow Futures
43,461.00 -107.00 (-0.25%) Nasdaq Futures
20,578.75 +85.00 (+0.41%) Russell 2000 Futures
2,323.70 +10.10 (+0.44%) Crude Oil
67.37 +0.35 (+0.52%) Gold
2,598.40 +28.30 (+1.10%)
IQV Dec 2024 250.000 call
- Business Wire
IQVIA CFO Ron Bruehlman to Speak at the UBS Global Healthcare Conference on November 13, 2024
RESEARCH TRIANGLE PARK, N.C., November 06, 2024--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the UBS Healthcare Conference in Rancho Palos Verdes, California on Wednesday, November 13, 2024 at 1:15 p.m. ET.
- TipRanks
Iqvia price target lowered to $265 from $280 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Iqvia (IQV) to $265 from $280 and keeps an Overweight rating on the shares. A “modest beat” in Q3 was led by better-than-expected TAS performance, but this is overshadowed by R&DS headwinds over the next twelve months, including a single large cancellation and two “mega trial delays” to 2025, the analyst tells investors in a post-earnings note. The firm views the risk/reward as attractive on the recent pullback, the analyst added. Published first
- Zacks
Interpreting IQVIA (IQV) International Revenue Trends
Evaluate IQVIA's (IQV) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
